Allakos Inc. announced a regulatory development concerning its listing status following the completion of a merger with Concentra Biosciences, LLC. As part of the merger consummation, Allakos requested The Nasdaq Global Select Market to suspend trading of its shares effective before the market opened on May 15, 2025. Additionally, the company requested Nasdaq to file a Notification of Removal from Listing to delist all its shares and deregister them under Section 12(b) of the Securities Exchange Act of 1934. Furthermore, the Surviving Corporation plans to file a Certification and Notice of Termination of Registration with the SEC, aiming to terminate the registration of its shares under Section 12(g) of the Exchange Act.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.